Cereno Scientific AB logo

CRNO TO1 B - Cereno Scientific AB News Story

SEK0.419 0.0  6.1%

Last Trade - 12:34pm

Sector
Healthcare
Size
Micro Cap
Market Cap £11.4m
Enterprise Value £6.61m
Revenue £n/a
Position in Universe 1538th / 1850

BRIEF-Cereno Scientific Signs CRO For Phase II Study With Drug Candidate CS1 In Rare Disease PAH

Thu 14th January, 2021 7:41am
Jan 14 (Reuters) - Cereno Scientific AB  CRNOSb.TE :
    * CERENO SCIENTIFIC SIGNS CRO FOR PHASE II STUDY WITH DRUG
CANDIDATE CS1 IN RARE DISEASE PAH
    * SIGNED A LETTER OF INTENT WITH THE GLOBAL CONTRACT
RESEARCH
ORGANIZATION (CRO) WORLDWIDE CLINICAL TRIALS
    * CLINICAL TRIAL APPLICATION PROCESS FOR THE STUDY HAS BEEN
INITIATED AND THE STUDY START IS EXPECTED TO BE INITIATED IN
MID-2021

Source text for Eikon:  ID: 
Further company coverage:  CRNOSb.TE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.